pharmaphorum
FEBRUARY 1, 2022
Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?
pharmaphorum
MAY 30, 2022
Josh Sackman, president and co-founder of AppliedVR, and Web Sun, president and co-founder of Komodo Health, relay how their newly formed collaboration reshapes the clinical trial process by using data, helping to cut costs and allowing for evaluation of broader patient populations. . Distinct offerings.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 9, 2023
The clinical trials landscape is evolving more rapidly than ever before. Meanwhile, decentralisation and the Big Data revolution are transforming the way researchers run clinical trials, and previously untapped geographies are emerging as new hubs for future research. Clinical trials management is no exception.
pharmaphorum
JANUARY 24, 2022
AI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘Big Data’ and data scientists within their R&D teams. Learn about the new breakthroughs within clinical trials and the treatment of disease. Who Should Attend?
pharmaphorum
FEBRUARY 11, 2022
Komodo’s Healthcare Map was previously used to help diagnose rare metastatic renal cell carcinoma patients, and Janssen Research & Development uses Komodo’s software for clinical trials for various therapeutic areas, including rare diseases. CZI has also partnered with large data collection agencies before.
Drug Discovery World
SEPTEMBER 6, 2022
And whilst clinical trials activity decreased by around 15% compared to 2020, last year still saw a number of regenerative medicines reach the bedside. For cell and gene therapies, Covid-19 was a “double-edged sword”, according to Kristin Thompson, Chief Business Officer at eureKARE. billion, compared to $19.9
XTalks
AUGUST 2, 2023
They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Lagevrio made up a large proportion of Merck’s revenue increase with $5.68 Toujeo generated Sanofi €1.12
Expert insights. Personalized for you.
88 
Let's personalize your content